|
Orthologous residues
|
|
CTNND1 (human): Y228‑p, CTNND1 iso3 (human): Y228‑p, CTNND1 iso4 (human): Y228‑p, CTNND1 iso14 (human): Y127‑p, CTNND1 (mouse): Y228‑p, CTNND1 iso3 (mouse): Y228‑p, CTNND1 (rat): Y228‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
electrophoretic mobility shift, mutation of modification site, phospho-antibody, western blotting
|
|
Disease tissue studied:
breast cancer, colorectal cancer, colorectal carcinoma, pancreatic cancer, pancreatic carcinoma
|
|
Relevant cell lines - cell types - tissues:
3T3 (fibroblast), A431 (epithelial), HCT116 (intestinal), HT-29 (intestinal), MDA-MB453 (breast cell), MDA-MB468 (breast cell), MIA PaCa-2 (pancreatic), SKBr3 (breast cell), SYF (fibroblast), T47D (breast cell)
|
|
Cellular systems studied:
cell lines
|
|
Species studied:
human, mouse
|
|
Enzymes shown to modify site in vitro:
|
|
|
|
Upstream Regulation
|
|
Potential in vivo enzymes for site:
|
|
Type
|
Enzyme
|
Evidence
|
Notes
|
|
KINASE
|
Src (human)
|
pharmacological inhibitor of upstream enzyme, transfection of wild-type enzyme, transfection of constitutively active enzyme, pharmacological activator of upstream enzyme, transfection of inactive enzyme, phospho-antibody
|
|
|
|
Comments:
not the only kinase as SYF cells still exhibit robust pY228 in +EGF
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
EGF
|
|
|
|
increase
|
|
|
SU6656
|
EGF
|
|
|
inhibit treatment-induced increase
|
slight decrease
|
|
SU6656
|
|
|
|
decrease
|
|
|
AG1478
|
|
|
|
decrease
|
|
|
EKI-785
|
|
|
|
decrease
|
|
|
PP1
|
|
|
|
decrease
|
|
|
low Ca(2+)
|
|
|
|
decrease
|
|
|
